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Aim: Rifampicin impregnated Dacron grafts have been shown to be effective at preventing vascular graft infection in 
different animal models. The development of resistance to rifampicin would be a major drawback to the widespread use of 
such a graft. We aimed to determine how readily this would occur by using a sheep animal model. 
Methods: Under general anaesthetic a 2cm long, 5mm diameter Dacron interposition graft inpregnated with 1.2 mg/ml 
rifampicin was placed in the left carotid artery. An extreme challenge of methicillin resistant Staphylococcus aureus 
(MRSA) using an inoculum of 109 colony forming units was placed directly onto the graft. The grafts were harvested at 
3 weeks and cultures of the graft and tissues were taken. The presence or absence of any abscess formation, anastomotic 
disruption and graft thrombosis was noted. Any positive growths were identified and if found to be the same as the 
inoculum, the bacteria were used as the inoculum for another sheep. This was repeated once more. Thus we started with 
three sheep initially and used a total of nine sheep. 
Results: There were no deaths. All grafts were infected with the same MRSA strain, confirmed on phage typing. There were 
three abscesses and one anastomotic disruption. Seven of the grafts were occluded. The minimal inhibitory concentration 
(MIC) of the infecting inoculum and the bacteria retrieved were determined using the agar dilutionaI method. The MIC for 
the three initial inocula was < O.O07mg/l. All subsequent strains isolated had an MIC of < O.015mg/l. This was a 
difference of one dilution and not significant. 
Conclusion: There was no development of rifampicin resistance using this animal model. 
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Introduction 
Vascular graft infection continues to be a significant 
complication of vascular surgery with an incidence 
between 1.3-3.4% 1-6 The incidence relates to whether 
the surgery 6 is elective, urgent or reoperative, the 
presence of a groin incision >6 or of a contaminated 
field 2"3 and whether autologous vein or prosthetic 
material is used. 2 Many measures and operative 
techniques have been advocated to diminish the 
frequency of its occurrence, 7' 8 most recently the use of 
an antibiotic impregnated graft. Antibiotics used have 
included 9 Silver-allantoin-heparin complex, oxacil- 
13 14 15 16 lin, 1°-12 amikacin, ' gentamicin, " tobramy- 
17 18 19 20 21 cin, " norfloxacin, ' penici l l in G, chlorampheni- 
14 22 2a - col and rifampicin. - Rifampicin has a very wide 
spectrum of activity and is especially active against 
coagulase positive and negative staphylococci, 26 these 
being the most commonly involved organisms in 
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vascular graft infections. 6-8 Initially rifampicin was 
added to Dacron passively by preclotting the graft in a 
mixture of lml  of rifampicin (at a concentration of 
60mg/ml) with 9ml of the animals' blood. Subsequent 
work showed that rifampicin bonded to gelatin sealed 
Dacron when the graft was soaked in the antibiotic 
solution. 27 Furthermore the rifampicin solution was 
effective at preventing raft infections from topical 24 
and intravenous 25 inoculation in different animal 
models24, 25 at a concentration of lmg/ml .  A Dacron 
graft soaked in a rifampicin solution at a concentration 
of 60mg/ml has been used successfully in the treat- 
ment of established vascular graft infections in 
patients. 2s Thus rifampicin combines a wide range of 
activity against he most appropriate organisms with 
ease of bonding to an existing vascular graft and 
would appear to be an ideal antibiotic to use. 
However the use of rifampicin clinically is beset 
by the problem of rapid development of resistance 26
and this could be a major problem if there was 
widespread adoption of the use of rifampicin impreg- 
nated grafts with the development of rifampicin 
1078-5884/95/030314 + 05 $08.00/0 © 1995 W. B. Saunders Company Ltd. 
Lack of Rifampicin Resistance Development 315 
resistant organisms. In the numerous animal studies 
published to date documenting the effectiveness of
rifampicin impregnated Dacron there has not been a 
failure on the basis of the development of rifampicin 
resistance, rather infection occurred when the bacte- 
rial challenge was overwhelming. 2~-25" 27, 29, 30 All 
these studies looked at a single exposure to rifampicin. 
We aimed in this study to determine how readily 
rifampicin resistance occurred when using an animal 
model to simulate repeated exposure to rifampicin, 
fully appreciative that this is a very unlikely clinical 
scenario. 
Methods 
A methicillin resistant Staphylococcus aureus (MRSA) 
isolated from a positive blood culture was the organ- 
ism used in this experiment. Twenty-four hours prior 
to operation the bacteria were plated out onto a horse 
blood agar plate and incubated for 24 h at 37°C. On 
the day of the experiment an inoculum of bacteria was 
diluted into 3 ml of normal saline to obtain a concen- 
tration of 109 colony forming units (c.f.u.) of bacteria 
as determined by MacFarland standardsY This con- 
centration was confirmed by culturing 0.1ml of the 
fifth tenfold serial dilution and then performing a
colony count after overnight incubation. 
We used sheep in this experiment on the basis of 
previous experience with the species. 24" 27, 29, 30, 32 This 
experiment was approved by the Animal Care and 
Ethics Committee of Westmead Hospital and the 
animals were housed and looked after according to set 
standards. The sheep were premedicated with xyla- 
zine, induced with thiopentone, intubated and then 
maintained on a combination of halothane and oxy- 
gen. The left side of the neck was shorn and prepared. 
Using a sterile technique an incision was made over 
the left internal jugular vein. 5000 units of heparin was 
given intravenously and the left jugular vein retracted 
ventrally to expose the underlying left common 
carotid artery. The artery was clamped and a lcm 
segment was excised. An interposition graft was 
placed using interrupted 6.0 polypropylene sutures. 
The graft used was a gelatin sealed Dacron graft 
(Gelsoft, Vascutek, Scotland) which had been soaked 
in a 1.2mg/ml rifampicin solution for 15 min at room 
temperature just prior to insertion. 
Haemostasis was checked, heparin was not 
reversed and no perioperative intravenous antibiotics 
were given. One ml of normal saline containing 109 
c.f.u, of MRSA was placed topically onto the graft and 
the skin closed using a 2.0 polypropylene suture. A 
sample of the bacteria was kept for phage typing and 
subsequent minimal inhibitory concentration determi- 
nations. The wound was sprayed with a topical 
antiparasitic agent. The sheep were recovered indoors 
overnight and after review the following morning, 
released to pasture. 
After 3 weeks the graft was harvested. The sheep 
was reanaesthetised and the wound reopened in a 
sterile fashion. A swab was taken of the perigraft 
tissues and this was rolled onto a horse blood agar 
plate. The graft was excised and the external surface 
was rolled onto a second horse blood agar plate. The 
lumen of the graft was irrigated three times with i ml 
of normal saline and the saline then flooded onto a 
third agar plate. A 0.5cm segment of the graft was 
excised and placed directly into brain heart infusion. 
All four cultures were then incubated for at least 48 
hours at 37°C. Any positive cultures were identified 
using standard bacteriological methods. If the organ- 
ism isolated was a Staphylococcus aureus then the 
antibiotic sensitivies were determined. Two samples 
were kept, one for phage typing and one for the 
determination f the minimal inhibitory concentration 
of the bacteria for rifampicin. 
At the time of graft harvest the presence or 
absence of graft patenc3~ anastomotic disruption and 
abscess formation was noted. 
It was initially intended to regraft the same 
animals with a second rifampicin impregnated graft, 
however as has previously been noted the sheep have 
a marked tendency towards graft thrombosis espe- 
cially in the presence of infection. 33 Thus we found 
that the artery at the time of harvest had often 
occluded all the way to the root of the neck. It was not 
possible to regraft hese animals without performing a 
much more invasive procedure. To overcome this, 
after we had established that the graft was infected 
with MRSA, we recultured the bacteria obtained from 
the graft as before and used a 109 c.f.u, inoculum on 
another animal. Thus we used three sheep initially 
and these were harvested after 3 weeks. After a 4-day 
delay in identifying the organism a further three sheep 
had a 109 c.f.u, inoculum placed onto a rifampicin 
impregnated Dacron graft. This was repeated once 
more. Thus we used nine sheep in total. 
All positive cultures of MRSA were phage typed 
to confirm that the retrieved organism was the same 
strain as the inoculum. 
Minimal inhibitory concentrations (MIC) for 
rifampicin were performed on all MRSA isolated. This 
was performed by the agar dilution method. Rifampi- 
cin was prepared in a range of concentrations from 
10mg/1 to 0.15mg/1. One ml of the appropriate antibi- 
otic concentration was added to 19ml of molten 
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Mueller Hinton broth and allowed to solidify. The 
bacteria to be tested and a control (NCTC 6571, with a 
known MIC of <0.007mg/1) were incubated the 
previous night and diluted to 107 c.f.u./ml. Using the 
Steers replicator the bacteria were placed onto the 
varying rifampicin concentration plates and incubated 
overnight at 37°C. The MIC was regarded as the 
lowest concentration at which complete inhibition 
occurred. 
Results 
All nine sheep were infected with the inoculating 
MRSA, confirmed on phage typing. All four cultures 
were positive in all nine animals. There were three 
abscesses and one anastomotic disruption. Seven of 
the grafts were occluded. 
The MIC for the three initial inocula was 
< 0.007mg/1. All subsequent s rains showed an MIC 
of < 0.015mg/1, this being a difference of only one 
dilution and not significant. There was no difference in 
the MIC of the bacteria isolated in the first, second or 
third groups of three sheep. 
Discussion 
Rifampicin resistance occurs readily when it is used 
for long periods in the clinical situation, especially 
when used as a single agent. 26 This resistance appears 
to happen on the basis of a mutation altering DNA- 
dependent RNA polymerase. 26There is concern that 
the widespread use of rifampicin impregnated Dacron 
grafts might lead to the development of rifampicin 
resistant organisms and thus negate an otherwise very 
effective antibiotic. 
Our present study looks only at repeated expo- 
sure of the same bacteria to rifampicin, up to three 
times. We found that when exposed to very high 
bacterial concentrations (109 c.f.u.) the sheep devel- 
oped an infection every time as determined by the 
presence of positive cultures, but that there was no 
development of resistance, as measured by the MIC. 
The MIC remained below 0.015rag/1 after three 
exposures to the rifampicin. Thus the grafts became 
infected on the basis of overwhelming bacterial load 
rather than the development of rifampicin resistance. 
It is important o note that our laboratory con- 
siders a staphylococcus to be resistant o rifampicin 
when its MIC is > lmg/1, and as can be seen from our 
results the retrieved bacteria MIC was considerably 
less than that and remained so. This is not surprising 
when the length of exposure to rifampicin is con- 
sidered. In vitro 27 data suggests that the rifampicin 
activity is present for only 4 days though a clinical 
case reported suggests that antibacterial activity is 
present up to 3 weeks. 2s Strachan et al. 28 suggest hat 
the amount of rifampicin present in a human aortic 
graft is at most 300mg. This short exposure to 
rifampicin can only be considered beneficial as it will 
minimise the development of resistance and yet 
provide activity at the critical time of the perioperative 
period when most graft infections are thought to 
become stablished. 7 
A topical inoculum of 109 c.f.u, of MRSA led to 
inevitable graft infection despite the presence of a 
rifampicin impregnated graft. Previous work has 
shown that rifampicin impregnated grafts will prevent 
graft infections in 90% of sheep exposed to a topical 
inoculum of 108 c.f.u, of Staphylococcus aureus. ~4 From 
this we conclude that the rifampicin impregnated 
graft (at the dose of 1.2mg/1) is not effective when 
used against larger bacterial loads, as in this experi~ 
ment. Presumably it is more effective when the 
bacterial inoculum is smaller. There must be a critical 
inoculum above which graft infection will inevitably 
occur (despite the presence of the rifampicin impreg- 
nated graft). We do not know whether the use of a 
greater concentration of rifampicin would alter this 
situation. 
Not all the grafts, despite being infected, dis~ 
played clinical evidence of infection, there being only 
three abscesses and one anastomotic disruption pre- 
sent at the time of graft harvest. The very high 
bacterial inoculum was used to ensure that the grafts 
did become infected, but it is perhaps urprising that 
only three of the nine sheep developed abscesses. 
Previous work has shown that the use of an inoculum 
of 108 c.f.u. MRSA led to abscess formation in eight 
out of ten sheep when rifampicin impregnated Dacron 
was not used. 35 Thus it is possible that the rifampicin 
did exert some effect at limiting bacterial growth but 
did not eliminate the bacteria. 
The numerous animal studies that have demon- 
strated the efficacy of rifampicin impregnated Dacron 
grafts have not shown any development of rifampicin 
resistance.2Z-25, 9, 3o Infections in the treatment arms of 
these studies are attributable to overwhelming bacte- 
rial challenge. It could be argued that these studies are 
not representative of the potential clinical situation of 
reoperative surgery. In our study we have looked at 
the likelihood of rifampicin resistance developing 
when bacteria (in this case MRSA) are repeatedly 
exposed to rifampicin. Bacteria were transplanted 
from one animal to another, which while not ideal 
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was felt to be the best approximation of repeated 
exposure to rifampicin impregnated Dacron graft. 
Whilst multiple vascular reconstructive procedures 
are often done in a single patient, they are usually 
spread over many months and many sites. Such a 
clinical situation would be very difficult to simulate. 
This study shows that there was no development 
of rifampicin resistance when sheep with a rifampicin 
impregnated Dacron graft in situ in their left carotid 
artery were exposed to a bacterial inoculum (109 c.f.u. 
MRSA) up to three times. The MIC of the retrieved 
bacteria remained <0.015mg/1. In the presence of 
such an overwhelming bacterial challenge, graft infec- 
tion inevitably occurred, as demonstrated by positive 
cultures. However, six of the nine grafts had no 
clinical evidence of infection at the time of harvest, 
indicating some effect from the rifampicin 
impregnation. 
We feel our results are encouraging for the 
continuing use of rifampicin impregnated Dacron 
grafts as we have demonstrated that rifampicin 
resistance is unlikely to occur. 
Acknowledgements 
This research was supported by a grant from Vascutek Limited. The 
graft material was also kindly provided by Vascutek Limited. The 
rifampicin was kindly provided by Marion Dow Pharmaceutical Pty 
Ltd. We gratefully acknowledge the contributions of these 
companies. 
All the phage typing was performed by Alison Vickery from the 
Department of Microbiology at the Royal Prince Alfred Hospital, 
Sydney. We thank her for her generous help. 
References 
1 FRY WJ AND LINDENAUER SM. Infection complicating the use of 
plastic arterial implants. Arch Surg 1967; 94: 600-609. 
2 SZILAGYI DE, SMITH RF, ELLIOT JP AND VRANDSCIC MP. Infection in 
arterial reconstruction with synthetic grafts. Ann Surg 1972; 176: 
321-333. 
3 GOLDSTONE J AND MOORE WS. Infection in vascular prostheses. 
Clinical manifestations and surgical management. Am J Surg 
1974; 128: 225-233. 
4 LIEKWEG WG AND GREENFIELD LJ. Vascular prosthetic infections: 
Collected experience and results of treatment. Surgery 1977; 81: 
335-342. 
5 LORENTZEN JE, NIELSEN OM, ARENDRUP I-I t KIMOSE HH, BILLE S, 
ANDERSEN Jr JENSEN CH, JACOBSEN F AND RODER OC. Vascular 
graft infection: An analysis of sixty-two graft infections in 2411 
consecutively implanted synthetic vascular grafts. Surgery 1985; 
98: 81-86. 
6 FLETCHER JP, DRYDEN M AND SORRELL TC. Infection of vascular 
prostheses. Aust N Z ] Surg 1991; 61: 432-435. 
7 BLUer TJ. Synthetic vascular graft infections. 1. Graft infections. 
Surgery 1983; 93: 733-746. 
80'BRIEN T AND COLLIN J. Prosthetic vascular graft infection Br J 
Surg 1992; 79: 1262--1267. 
9 CLARK RE AND MARGRAF HW. Antibacterial vascular grafts with 
improved thromboresistance. Arch Surg 1974; 109: 159-162. 
10 HARVEY RA AND GRECO RS. The noncovalent bonding of 
antibiotics to a polytetrafluoroethylene-benzalkonium graft. Ann 
Surg 1981; 194: 642--647. 
11 WEBB LX, MYERS R% CORDELL AR, HOBGOOD CD, COSTERTON JW 
AND GRISTINA AG. Inhibition of bacterial adhesion by anti- 
bacterial surface pretreatment of vascular prostheses. J Vasc Surg 
1986; 4: 16-21. 
12 SI-rUE WB, WOROSILO SC, DON~TZ AP, TROOSKIN SZ, HARVEY RA 
AND GRECO RS. Prevention of vascular prosthetic infection with 
an antibiotic-bonded Dacron graft. J Vasc Surg 1988; 8: 600-605. 
13 MOORE WS, CHVAPIL M, SEIFFERT G AND KEOWN K. Development 
of an infection-resistant vascular prosthesis. Arch Surg 1981; 116: 
1403-1407. 
14 CHSRVU A, MOORE WS, CHVAPIL M AND HENDERSON T. Efficacy 
and duration of antistaphylococcal activity comparing three 
antibiotics bonded to Dacron vascular grafts with a collagen 
release system. J Vasc Surg 1991; 13: 897-901. 
15 NIELSEN OM, NOER HH, JORGENSEN LG AND LORENTZEN JE. 
Gentamicin beads in the treatment of localised vascular graft 
infection-long term results in 17 cases. Cur J Vasc Surg 1991; 5: 
283-285. 
16 HAVERICH A, HIRT S, KARCK M, SICLARI F AND WAHLIG H. 
Prevention of graft infection by bonding of gentamicin to Dacron 
prostheses. J Vasc Surg 1992; 15: 187-193. 
17 SHENK JS, NEY AL, TSUKAYAMA DT, OLSON ME AND BUBRICK MP. 
Tobramycin-adhesive in preventing and treating PTFE vascular 
graft infections. J Surg Res 1989; 47: 487-492. 
18 NEY AL, KELLY PH, TSUKAYAMA DT AND BUBRICK MP. Fibrin glue- 
antibiotic suspension in the prevention of prosthetic graft 
infection. J Trauma 1990; 30: 1000-1006. 
19 SHAH PM, MODAL S, Fox CL, BABU SC, SAMPATH L, CLAUSS RH 
AND STAHL WM. PTFE graft treated with silver norfloxacin 
(AgNF): drug retention and resistance to bacterial challenge. J 
Surg Res 1987; 42: 298-303. 
20 MODAL SM, SAMPATH L, Fox CL, BENVENISTY A, NOWYGROD R AND 
REEMSTMAU K. A new method for the direct incorporation of 
antibiotic in prosthetic vascular grafts. S G O 1987; 164: 
143-147. 
21 GRECO RS, TROOSKIN SZ, DONETZ AP AND HARVEY RA. The 
application of antibiotic bonding to the treatment of established 
vascular prosthetic infection. Arch Surg 1985; 120: 71-75. 
22 POWELL TW, BURNHAM SJ AND JOHNSON G Jr. A passive system 
using rifampicin to create an infection-resistant vascular pros- 
thesis. Surgery 1983; 94: 765-769. 
23 McDoUGAL EG, BURNHAM SJ AND JOHNSON G Jr. Rifampicin 
protection against experimental graft sepsis. J Vasc Surg 1986; 4: 
5-7. 
24 AVRAMOVIC JR AND FLETCHER JP. Rifampicin impregnation of a 
protein-sealed Dacron graft: an infection resistant vascular graft. 
Aust N Z J Surg 1991; 61: 436-440. 
25 GOEAU-BRISSONNIERE O, LEPORT C, BACOURT F/LEBRAULT C, COMTE 
R AND PECHERE JC. Prevention of vascular graft infection by 
rifampicin bonding to a gelatin-sealed Dacron graft. Ann Vasc 
Surg 1991; 5: 408-412. 
26 FARR B AND MANDELL GL. Rifampicin. Med Clin N Am 1982; 66: 
157-168. 
27 ASHTON TR, CUNNINGHAM JW, PATON D AND MAINI R. Antibiotic 
loading of vascular grafts. Presented at the 16th Annual Meeting 
of the Society for Biomaterials, Ma~ Charlestown, South 
Carolina. 
28 STRACHAN CJL, NEWSOM SWB AND ASHTON TR. The clinical use of 
an antibiotic-bonded graft. Cur J Vasc Surg 1991; 5: 627-632. 
29 AVRAMOVIC J AND FLETCHER JP. Prevention of prosthetic vascular 
graft infection by rifampicin impregnation of a protein-sealed 
Dacron graft in combination with parenteral cephalosporin. J 
Cardiovasc Surg 1992; 33: 70-74. 
30 FLETCHER JP~ AVRAMOVIC J, KENNY J AND SARDELIC E Increased 
resistance to Staphylococcal graft infection by rifampicin 
impregnation of gelatin sealed Dacron. In: Modern Vascular 
Surgery, volume 6. Editor JB Chang; Springer-Verlag New York, 
1994. 483-487. 
Cur J Vasc Endovasc Surg Vol 9, April 1995 
318 F. Sardelic et al. 
31 GENNETTE EH, BALOWS A, HAUSLER WJ Jr AND SHADOMY HJ. 
Manual of Clinical Microbiology, 4th Edition, 1985, American 
Society for Microbiology-Washington. 
32 FLETCHER JPI DRYDEN M, MUNRO R, Xu JH AND HEHIR MD. 
Establishment of a vascular graft infection model in the sheep 
carotid artery. Aust N Z ] Surg 1990; 60: 801-803. 
33 SARDELIC F~ AO PY, Bmous M AND FLETCHER JP. Comparison of a 
fluoropolymer passivated Dacron (FPD) graft with PTFE graft in 
a sheep model. Cardiovasc Surg 1994; 2: 237-247. 
34 Rlca MA, MEHRAN RJ, PETSIKAS D, MOHAMED F, GUIDON R, 
MAROIS YI CHRISTOU NV, GRAHAM A AND SYMES JE Species 
differences in the infectability of vascular grafts. ] Investigative 
Surg 1991; 4: 45-52. 
35 SARDELIC F, AO PY AND FLETCHER JP. Efficacy of rifampicin 
impregnated graft in reducing methicillin resistant Staphylococ- 
cus aureus vascular graft infection in a sheep model. Surg Res 
Comm 1994; 15: 205-210. 
Accepted 5 October 1994 
Eur J Vasc Endovasc Surg Vol 9, April 1995 
